Characterizing resistance in a subset of breast cancer

Fvasconcellos [Public domain] via Wikimedia Commons

About 20% of breast cancers have elevated levels of the protein HER2. Treatment with drugs that target HER2, such as a combination of trastuzumab and lapatinib, can lead to improved outcomes in such cases, but many tumors eventually become resistant to this therapy. Joan T. Garrett (Vanderbilt University Medical Center, Nashville, TN) studied the development of resistance in HER2-positive breast cancer with the goal of identifying better treatment strategies for these tumors.

Lab Anim. (NY) 43, 181 (2014).
view full text (login required)

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: